Ocular Therapeutix Inc


Prices are adjusted according to historical splits.

Ocular Therapeutix Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$308.01 million
Book Value:
Revenue TTM:
$54.60 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Ocular Therapeutix Inc had its IPO on 2014-07-25 under the ticker symbol OCUL.

The company operates in the Healthcare sector and Biotechnology industry. Ocular Therapeutix Inc has a staff strength of 274 employees.

Stock update

Shares of Ocular Therapeutix Inc opened at $3.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.64 - $3.89, and closed at $3.66.

This is a -5.67% slip from the previous day's closing price.

A total volume of 454,016 shares were traded at the close of the day’s session.

In the last one week, shares of Ocular Therapeutix Inc have slipped by -5.43%.

Ocular Therapeutix Inc's Key Ratios

Ocular Therapeutix Inc has a market cap of $308.01 million, indicating a price to book ratio of 4.8976 and a price to sales ratio of 4.1736.

In the last 12-months Ocular Therapeutix Inc’s revenue was $54.60 million with a gross profit of $-6508000 and an EBITDA of $-81890000. The EBITDA ratio measures Ocular Therapeutix Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ocular Therapeutix Inc’s operating margin was -153.89% while its return on assets stood at -35.53% with a return of equity of -263.41%.

In Q2, Ocular Therapeutix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 23.8%.

Ocular Therapeutix Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ocular Therapeutix Inc’s profitability.

Ocular Therapeutix Inc stock is trading at a EV to sales ratio of 3.3213 and a EV to EBITDA ratio of -3.2833. Its price to sales ratio in the trailing 12-months stood at 4.1736.

Ocular Therapeutix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$122.56 million
Total Liabilities
$32.36 million
Operating Cash Flow
Capital Expenditure
$1.99 million
Dividend Payout Ratio

Ocular Therapeutix Inc ended 2023 with $122.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $122.56 million while shareholder equity stood at $3.09 million.

Ocular Therapeutix Inc ended 2023 with $11.78 million in deferred long-term liabilities, $32.36 million in other current liabilities, 8000.00 in common stock, $-667842000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $66.61 million and cash and short-term investments were $66.61 million. The company’s total short-term debt was $3,796,000 while long-term debt stood at $53.28 million.

Ocular Therapeutix Inc’s total current assets stands at $100.71 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.31 million compared to accounts payable of $3.57 million and inventory worth $2.20 million.

In 2023, Ocular Therapeutix Inc's operating cash flow was $-1990000.00 while its capital expenditure stood at $1.99 million.

Comparatively, Ocular Therapeutix Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Ocular Therapeutix Inc stock is currently trading at $3.66 per share. It touched a 52-week high of $7.96 and a 52-week low of $7.96. Analysts tracking the stock have a 12-month average target price of $13.13.

Its 50-day moving average was $4.29 and 200-day moving average was $4.76 The short ratio stood at 5.72 indicating a short percent outstanding of 0%.

Around 518.5% of the company’s stock are held by insiders while 5213.3% are held by institutions.

Frequently Asked Questions About Ocular Therapeutix Inc

The stock symbol (also called stock or share ticker) of Ocular Therapeutix Inc is OCUL

The IPO of Ocular Therapeutix Inc took place on 2014-07-25

Similar Industry Stocks (Biotechnology)

Last Price
Aarons Inc (AAN)
Pontem Corp (PNTM)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.


24 Crosby Drive, Bedford, MA, United States, 01730